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Abstract
Introduction: Follistatin-like protein 1 (FSTL1) is a proinflammation mediator implicated in arthritis in rodent animal
models. The present study is aimed at assessing FSTL1 levels in systemic autoimmune diseases and correlating
them with disease activity in patients with rheumatoid arthritis (RA).
Methods: Serum FSTL1 levels from 487 patients with systemic autoimmune diseases and 69 healthy individuals
were measured by enzyme-linked immunosorbent assay (ELISA). FSTL1 expression in synovial fluid (SF) and synovial
tissues (STs) was determined by ELISA, immunohistochemistry, real-time polymerase chain reaction (RT-PCR) and
western blot analysis in RA patients and trauma controls. FSTL1 levels in fibroblast-like synoviocytes (FLSs) from RA
patients were determined by real-time PCR and western blot analysis.
Results: Serum FSTL1 levels were significantly elevated in patients with RA, ulcerative colitis, systemic lupus
erythematosus, Sjögren’s syndrome (SS), systemic sclerosis and polymyositis/dermatomyositis. Serum FSTL1 levels in
the RA and secondary SS patients were substantially higher than those in other patients. Serum FSTL1 levels were
increased in early RA, rheumatoid factor (RF)- and anti-cyclic citrullinated peptide antibody (ACPA)-negative
patients compared to healthy controls. Moreover, serum FSTL1 concentrations were significantly higher in long-
standing RA patients than in early RA patients and in the RF- and ACPA-positive RA patients than in RF- and ACPA-
negative RA patients. Elevated FSTL1 levels in the STs and SF of RA patients were also observed. FSTL1 levels in
serum were markedly higher than those in SF in RA patients. The strongest FSTL1 staining was detected in the
cytoplasm of synovial and capillary endothelial cells from RA synovium. Furthermore, FSTL1 was induced in FLSs by
inflammatory mediators. Importantly, serum FSTL1 levels were correlated with several important biologic and
clinical markers of disease activity, including erythrocyte sedimentation rate, C-reactive protein, RF, ACPA, swollen
joint count, patient global visual analogue scale score and Disease Activity Score 28 in the adult RA patient
population. Notably, serum FSTL1 levels were significantly diminished following successful treatment and clinical
improvement.
Conclusions: Elevated FSTL1 levels reflect not only joint diseases but also inflammation and tissue degradation in
systemic autoimmune diseases. Serum FSTL1 levels may thus serve as a serological inflammatory marker of disease
activity in RA patients.
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Follistatin-like protein 1 (FSTL1) is a secreted glycopro-
tein with extensive glycosylation modifications and
exists in two isoforms that differ in the extent of sialyla-
tion [1]. It is widely expressed in all organs [2] and is
also detectable in the medium of cardiac myocytes [3]
and endothelial cells (ECs) [4]. FSTL1 expression is
upregulated in cardiac and skeleton myocytes in
response to ischemic stress [4] and in the osteoblast cell
line stimulated with proinflammation cytokines [5]. It
has been shown that FSTL1 functions as an antiapopto-
tic protein by increasing both Akt and extracellular sig-
nal-regulated kinase activities [3]. FSTL1 promotes EC
function and stimulates revascularization through activa-
tion of the Akt-endothelial nitric oxide synthase signal-
ing pathway [4]. FSTL1 serum concentrations have been
assessed in healthy individuals and in patients with
acute coronary syndrome and were found to correlate
with disease mortality during follow-up [6].
Rheumatoid arthritis (RA) is characterized by persis-
tent multiple synovial inflammation and joint destruc-
tion. FSTL1 has also been reported to be involved in the
pathogenesis of RA. Tanaka et al. [7] first identified it as
an autoantigen when FSTL1 autoantibodies were found
in the serum and synovial fluid (SF) of RA patients.
Furthermore, FSTL1 mRNA is upregulated in the RA
synovium [8] and the inflammatory synovial pannus of
the collagen-induced arthritis (CIA) mouse [9]. Recently,
it has been demonstrated that FSTL1 is a novel proin-
flammatory molecule. Overexpression of FSTL1 in
macrophages and fibroblasts augments the activity of
proinflammatory cytokines, including interleukin (IL)-
1b, tumor necrosis factor a (TNFa), and IL-6 and
causes severe arthritis in the normal mouse [10]. FSTL1
neutralization was shown to ameliorate arthritis by inhi-
biting production of interferon (IFN)-g and chemokine
(C-X-C motif) ligand 10 in arthritic joints of CIA mice
[5]. The aims of the present study were to determine
FSTL1 levels in patients with systemic autoimmune dis-
eases and to further assess the relationship between
serum FSTL1 levels and RA disease progression.
Materials and methods
Subjects
Peripheral blood was collected by venipuncture from
patients with systemic autoimmune diseases, comprising
the following: 207 RA, 22 reactive arthritis (ReA), 34 psor-
iatic arthritis (PsA), 33 ankylosing spondylitis (AS), 20
Crohn’s disease (CD), 22 ulcerative colitis (UC), 40 sys-
temic lupus erythematosus (SLE), 16 primary and 28 sec-
ondary Sjögren’s syndrome (pSS and sSS, respectively), 22
systemic sclerosis (SSc) and 43 polymyositis/dermatomyo-
sitis (PM/DM). All patients included in this study were
diagnosed according to the respective diagnostic criteria
for those diseases [11-19]. We included a total of 69
apparently healthy individuals (HC) without regular medi-
cation or chronic drug or alcohol abuse or other chronic
disease or acute illness. Their demographic, clinical and
laboratory characteristics are summarized in Tables 1
and 2. Serum was acquired and stored immediately at
-20°C. Erythrocyte sedimentation rate (ESR) was measured
by the Westergren method. Serum C-reactive protein
(CRP) and rheumatoid factor (RF) levels were determined
in the clinical laboratory using a latex photometric immu-
noassay. Anti-cyclic citrullinated peptide (CCP) antibodies
(ACPAs) were detected using a commercial anti-CCP2
enzyme-linked immunosorbent assay (ELISA) kit (Fuchun
Kexin Biotech, Shanghai, China) following the manufac-
turer’s instructions. Among 207 RA patients, RF-positive
patients (RF >20 IU/ml) and ACPA-positive patients
(ACPA >50 RU/ml) accounted for 71.5% and 73.8% of the
RA population, respectively. There were 48 early RA
patients (disease duration ≤6 months) who accounted for
23.2% of the RA population. In addition, 81 patients were
assessed by a composite Disease Activity Score 28
(DAS28) [20] using the ESR, the numbers of swollen and
tender joints and the global assessment of the patients’ dis-
ease activity. We recruited RA patients without treatment
or treated with disease-modifying antirheumatic drugs
(DMARDs), biological drugs and corticosteroids alone or
in combination. Finally, 20 of these patients were success-
fully followed up after 6 months of treatment with inflixi-
mab and/or DMARDs. The efficacy assessment for each
patient was based on the ACR preliminary definition of
improvement in RA. Responders achieved at least an
ACR20 response (that is, improvement of ≥20% according
to the American College of Rheumatology (ACR) response
criteria). Nonresponders did not achieve an ACR20
response.
Synovial tissues (STs) from another cohort of 14 RA
patients (median age, 53 years; median disease duration,
6.5 years; median DAS28 score, 4.3) were obtained by
total knee joint replacement or arthroscopic synovectomy.
Each sample was inspected visually to ensure that only
inflamed tissue was included. Control samples were taken
from 13 trauma patients with normal synovium. Most of
tissue samples were split into three parts: one was stored
at -70°C for mRNA and protein extraction, one was fixed
in 4% paraformaldehyde and embedded in paraffin and
one was minced and used for separation of synovial cells
immediately upon acquisition. SF was collected from most
of these patients during knee joint surgery.
Collection of ST, SF and peripheral blood samples was
performed according to the medical ethics regulations of
Nanjing Medical University. This study was approved by
the Nanjing Medical University Review Board, and writ-
ten permission was requested and received from all
patients and healthy individuals in the study.
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Serum FSTL1 levels were measured using a standard
quantitative sandwich ELISA (Groundwork Biotechnol-
ogy Diagnosticate, San Diego, CA, USA) with a 100 pg/
ml detection limit of sensitivity. Serum and SF samples
were diluted 1:5 and 1:10 in phosphate-buffered saline,
respectively. Concentrations were reported as micro-
grams per liter. All analyses and calibrations were per-
formed in duplicate. Optical densities were determined
using an absorbance microplate reader (Elx808™ Bio-
Tek Instruments, Winooski, VT, USA) at 450 nm. Gen5
Data Analysis software (BioTek Instruments) was used
to analyze all materials and depict the standard curve.
Real-time PCR
Total RNA was extracted from minced cryogenic tissues
or cultured fibroblast-like synoviocytes (FLSs) using the
miRNeasy Mini Kit (Qiagen, Basel, Switzerland) accord-
ing to the manufacturer’s instructions. On-column
digestion of contaminated DNA was performed using
the RNase-Free DNase Set (Qiagen). Total RNA (2 μg)
was reverse-transcribed using the ReverTra Ace kit
(Toyobo, Osaka, Japan) according to the manufacturer’s
instructions. A quantitative real-time polymerase chain
reaction (RT-PCR) assay was performed using SYBR
Green (Toyobo) in an Applied Biosystems 7900HT
Sequence Detection System (Applied Biosystems, Foster
City, CA, USA). Primer sequences for amplifying FSTL1
cDNA and internal control glyceraldehyde 3-phosphate
dehydrogenase (GAPDH) were as follows: FSTL1, 5’-
CGATGGACACTGCAAAGAGA-3’ (forward) and 5’-
CCAGCCATCTGGAATGATCT-3’ (reverse); GAPDH,
5’-AGGGCTGCTTTTAACTCTGGT-3’ (forward) and
5’-CCCCACTTGATTTTGGAGGGA-3’ (reverse). The
comparative threshold cycle method was used for rela-
tive quantification of mRNA.
Western blot analysis
Minced cryogenic tissues or cultured FLSs were lysed
and boiled in sodium dodecyl sulfate (SDS) Lamini buf-
fer. SDS-polyacrylamide gel electrophoresis was per-
formed on 10% polyacrylamide gel and transferred to
Table 1 Characteristics and serum FSTL1 levels of the subjects investigated
a
Characteristics RA ReA PsA AS CD UC SLE pSS sSS SSc PM/DM HC
Total number of subjects 207 22 34 33 20 22 40 16 28 22 43 69
Age
b, years 54 23.5 46.5 44 33 35 37 50 53 53.5 41 38
25th percentile 43.5 13.8 33 29.5 25.5 29.3 31.3 48 39.3 43.5 26 27
75th percentile 63 33.5 54 51 43 45.8 52.3 63 63 58 58 41
Number of female/male subjects 159/48 8/14 15/19 9/24 6/14 9/13 34/6 14/2 24/4 17/5 31/12 37/32
Disease duration
b, years 3 20 days 52344232 1 -
25th percentile 0.5 13 days 311211110 . 3-
75th percentile 10 75 days 74676485 2 -
Serum FSTL1 levels, μg/l
Geometric mean 74.28 3.74 7.57 6.19 6.39 13.61 14.60 29.94 73.88 16.48 13.79 6.49
Lower 95% CI 60.89 2.73 4.99 5.03 5.35 9.71 10.49 15.76 45.79 7.81 9.97 5.89
Upper 95% CI 90.60 5.12 11.48 7.62 7.63 19.06 20.30 56.88 119.20 34.76 19.06 7.15
RSD (%) 129.17 104.58 134.90 63.33 39.06 112.35 115.27 148.22 117.81 133.00 186.28 36.71
Median 71.27 3.71 4.52 5.21 6.05 10.78 12.92 34.81 82.48 25.01 10.74 6.60
25th percentile 25.51 2.49 3.47 3.67 4.92 7.48 6.84 10.51 23.48 3.38 6.76 5.28
75th percentile 236.70 5.46 29.59 9.37 8.55 28.24 34.12 47.37 169.70 62.68 29.60 8.19
Above normal, %
c 87.43 9.09 26.47 18.18 5 36.36 52.5 68.75 96.43 54.55 48.84 4.3
P versus HC <0.001 <0.001 0.100 0.375 0.627 <0.001 <0.001 <0.001 <0.001 <0.001 0.018 -
P versus RA - <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 0.013 0.937 <0.001 <0.001 <0.001
aFSTL1, follistatin-like protein 1; 95% CI, 95% confidence interval; -, not determined; RSD, relative standard deviation; HC, healthy individuals; RA, rheumatoid
arthritis; ReA, reactive arthritis; PsA, psoriatic arthritis; AS, ankylosing spondylitis; CD, Crohn’s disease; UC, ulcerative colitis; SLE, systemic lupus erythematosus;
pSS, primary Sjögren’s syndrome; sSS, secondary Sjögren’s syndrome; SSc, systemic sclerosis; PM/DM, polymyositis/dermatomyositis;
bmedian;
cnormal range
denoted as mean + 2 SD was 12 μg/l.
Table 2 Disease characteristics of RA patients
investigated
a
Characteristics n Median (25th to 75th percentile)
ESR, mm/h 199 33 (17 to 61)
CRP, mg/l 207 8.1 (2.5 to 33.6)
RF, IU/ml 207 63.6 (15 to 185.5)
ACPA, RU/ml 206 251.9 (42.65 to 650.7)
Tender joint count 81 4 (2 to 7)
Swollen joint count 81 2 (1 to 5)
Patient global VAS score 81 50 (30 to 70)
DAS28 score 81 4.7 (3.4 to 5.6)
aRA, rheumatoid arthritis; ESR, erythrocyte sedimentation rate; CRP, C-reactive
protein; RF, rheumatoid factor; IU, international units; RU, relative units; ACPA,
anti-cyclic citrullinated peptide antibody; VAS, visual analogue scale; DAS28,
disease activity score 28.
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clonal antibody (R&D Systems, Minneapolis, MN, USA)
and actin AC-40 (Sigma-Aldrich, St. Louis, MO, USA)
were used to detect FSTL1 and b-actin expression,
respectively.
Immunohistochemistry
Immunohistochemical staining with polyclonal
anti-FSTL1 antibody was performed on archival forma-
lin-fixed, paraffin-embedded ST using the peroxidase
technique. Briefly, sections were deparaffinized and
rehydrated. Epitope retrieval was performed in citrate
buffer (pH 6) in a water bath at 98°C for 35 minutes
with cooling for 20 minutes before immunostaining.
Tissues were incubated with the primary anti-FSTL1
antibody (1:400 dilution) overnight at 4°C after blocking
and then exposed to biotinylated secondary linking anti-
body (Boster, Wuhan, China) for 20 minutes. Biotin
detection was performed with peroxidase-conjugated
streptavidin. Finally, the slides were incubated with 3,3’-
diaminobenzidine (Boster) for about 5 to 10 minutes
and with hematoxylin as a counterstain for 1 minute.
Sections were washed between incubations with Tris-
buffered saline buffer (pH 7.6). Goat polyclonal antibody
immunoglobulin G (IgG) was used as a negative control
throughout. Each section was examined independently
by two investigators (DL and YW) in a blinded manner.
Isolation and culture of human synovial fibroblasts
ST specimens were obtained from patients with RA or
trauma by synovectomy or joint replacement surgery.
These joint tissues were minced and incubated with
1 mg/ml collagenase I (Sigma-Aldrich, St. Louis, MO,
USA) in serum-free Dulbecco’s modified Eagle’s medium
(DMEM) (Gibco BRL, Grand Island, NY, USA) for
4 hours at 37°C, filtered through a nylon mesh, exten-
sively washed and cultured in DMEM supplemented with
10% fetal calf serum (Gibco), 100 U of penicillin, 100 μg/
ml streptomycin, and 2 mM L-glutamine in a humidified
atmosphere containing 5% CO2. After overnight culture,
the nonadherent cells were removed. The adherent cells
were split at a ratio of 1:3 after these cells grew to 80%
confluence. Synoviocytes were used from passages 4
through 6 in these experiments, during which they con-
sisted of a homogeneous population of FLSs.
Reagents and stimulation assays
Cultured FLSs were grown in 100-mm cell culture dishes
(6 to 8 × 10
5 cells/dish). Cultures were stimulated for
24 hours for mRNA extraction or for 36 hours for pro-
tein collection with the following agents: 20 μg/ml polyi-
nosinic:polycytidylic acid (InvivoGen, San Diego, CA,
USA), 100 ng/ml lipopolysaccharide from Escherichia
coli (Sigma-Aldrich), 300 ng/ml bacterial lipoprotein
(InvivoGen), 10 ng/ml recombinant interleukin-1b
(IL-1b) (Invitrogen, Carlsbad, CA, USA), 10 ng/ml tumor
necrosis factor a (TNFa)( I n v i t r o g e n )a n d1 0n g / m l
transforming factor b (TGFb) (Invitrogen).
Statistical analysis
Statistical analyses were performed using Prism and
Instat software (GraphPad Software, San Diego, CA,
USA) and SPSS 13.0 software (SPSS Inc., Chicago, IL,
USA). The significance of the differences was evaluated
using the Kruskal-Wallis test among multiple groups
and the Mann-Whitney U test between groups. Follow-
up data were evaluated by the Wilcoxon matched pairs
test. The relationships between serum FSTL1 levels and
other parameters were evaluated using Spearman’s rank-
correlation test. All quoted P values were two-tailed,
and P values less than 0.05 were considered significant.
Serum FSTL1 levels that were not normally distributed
were transformed to their natural logarithm (ln) for the
regression analyses. Linear multiple regression analyses
were performed with ln(FSTL1) levels as dependent vari-
ables and the raw data of CRP, ESR, RF, ACPA, disease
duration, sex and age as independent variables. The test for
significance of regression is carried out using the analysis
of variance. The t-test was used to check the significance
of individual regression coefficients in the multiple linear
regression model. The level of significance was set at 0.05.
Results
Serum FSTL1 levels in patients with systemic autoimmune
diseases
Serum FSTL1 levels and their distributions were deter-
mined for the various groups and found to differ signifi-
cantly between patient groups and HC (Figure 1 and
T a b l e1 ;F i g u r eS 1a n dT a b l eS 1i nA d d i t i o n a lf i l e1 ) .
Serum FSTL1 levels in the RA and sSS groups were
substantially higher than those found in the other
patient groups and HC. Serum FSTL1 levels in the pSS,
SLE, SSc, PM/DM and UC patient groups were also sig-
nificantly higher than those in HC. No significant differ-
ence was observed in serum FSTL1 levels between the
PsA, CD and AS patient groups and HC. However,
serum FSTL1 concentrations in ReA were significantly
lower than those in HC. UC patients showed higher
serum FSTL1 levels than CD patients.
Serum FSTL1 levels in the subgroups of RA patients
Furthermore, we compared serum FSTL1 levels between
early and long-standing RA patients (Figure 2). Early RA
patients showed increased serum FSTL1 levels (median,
48.4 μg/l; 25th to 75th percentile, 18.6 to 108.4 μg/l)
compared with HC. Serum FSTL1 levels in long-
standing RA patients (median, 82.7 μg/l; 25th to 75th
percentile, 28.2 to 307.5 μg/l) were higher than those in
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FSTL1 levels of RF- and ACPA-positive RA patients
with those of RF- and ACPA-negative RA patients (Fig-
ure 2). The serum FSTL1 levels in RF-negative RA
patients (median, 27.1 μg/l, 25th to 75th percentile, 11.8
to 70.0 μg/l) and ACPA-negative RA patients (median,
25.8 μg/l, 25th to 75th percentile, 13.3 to 71.8 μg/l)
were higher than those in HC. In addition, FSTL1 levels
in the RF-positive patients (median, 108.8 μg/l, 25th to
75th percentile, 40.5 to 366.4 μg/l) and ACPA-positive
patients (median, 98.3 μg/l, 25th to 75th percentile, 35.6
to 359.9 μg/l) were higher than those of their RF-nega-
tive and ACPA-negative counterparts.
Elevated FSTL1 expression in ST and SF in patients
with RA
It was previously reported that FSTL1 mRNA was over-
expressed in STs of RA [8]. We confirmed these results
and found that FSTL1 mRNA levels were increased by
approximately 1.52-fold in S T sf r o mR Ap a t i e n t sc o m -
pared to the trauma controls (Figure 3A). Furthermore,
the FSTL1 protein levels were analyzed from representa-
tive samples by Western blot analysis. Consistent with
the elevation of its transcript, FSTL1 protein expression
was markedly increased in RA patients’ STs compared
with those in the trauma controls (Figure 3B). The spe-
cificity of FSTL1 antibodies was confirmed because no
nonspecific band was detected on immunoblot imaging
studies. Furthermore, FSTL1 levels in SF from RA
patients (mean ± SEM, 24.8 ± 3.6 μg/l) were signifi-
cantly higher than those of the trauma controls (mean ±
SEM, 6.59 ± 0.9 μg/l). Interestingly, serum FSTL1 levels
(mean ± SEM, 182.8 ± 16.4 μg/l) were dramatically
higher than SF FSTL1 levels in RA patients. In contrast,
no difference was found between serum and SF FSTL1
levels in the control group (Figure 3C).
Figure 1 Serum concentrations of FSTL1 in HC (n = 69) and patients with RA (n = 207), ReA (n =2 2 ) ,P s A( n = 34), AS (n = 33), CD
(n = 20), UC (n = 22), SLE (n = 40), pSS (n = 16), sSS (n = 28), SSc (n = 22) and PM/DM (n = 43). Horizontal lines represent median values.
Each point represents an individual value. FSTL1, follistatin-like protein 1; HC, healthy individuals; RA, rheumatoid arthritis; ReA, reactive arthritis;
PsA, psoriatic arthritis; AS, ankylosing spondylitis; CD, Crohn’s disease; UC, ulcerative colitis; SLE, systemic lupus erythematosus; pSS, primary
Sjögren’s syndrome; sSS, secondary Sjögren’s syndrome; SSc, systemic sclerosis; PM/DM, polymyositis/dermatomyositis.
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patients with RA
We next assessed FSTL1 tissue distributions in STs
from RA patients and trauma controls (Figure 4). In
normal synovium from trauma controls, FSTL1 staining
was weak but positive in comparison to the IgG control,
suggesting that FSTL1 was constitutively expressed,
albeit at relatively low levels, in these tissues. A signifi-
cant increase in FSTL1 staining was seen in STs from
RA patients compared with trauma controls. FSTL1
staining was mainly seen in the cytoplasm of synovio-
cytes from lining and sublining, the major cell types pre-
sent in synovium. FSTL1 expression was also evident in
ECs of capillaries from STs of RA patients, but was
much weaker and even absent in ECs from normal STs
of trauma controls. In contrast, FSTL1 was not detect-
able in most infiltrated lymphocytes.
Increased FSTL1 expression in FLSs from RA patients
induced by proinflammatory mediators
To determine whether FLSs are a source of tissue for
FSTL1, we separated primary FLSs and compared
FSTL1 expression in FLSs from RA patients and trauma
c o n t r o l s .N od i f f e r e n c ei nF S T L 1l e v e l sw a ss e e ni n
FLSs (data not shown), suggesting that FSTL1 produc-
tion in FLSs is dependent on an inflammatory milieu.
Next, we selected six primary FLSs derived from differ-
ent RA patients and stimulated them with inflammatory
Figure 2 Serum FSTL1 levels in HC (n = 69), early RA patients (n = 48), long-standing RA patients (n = 159), RF-negative RA patients
(n = 59), RF-positive RA patients (n = 148), ACPA-negative patients (n = 54) and ACPA-positive patients (n = 152). Horizontal lines
represent median values. Each point represents an individual value (*P < 0.05; ****P < 0.0001). FSTL1, follistatin-like protein 1; HC, healthy
individuals; RA, rheumatoid arthritis; RF, rheumatoid factor; ACPA, anti-cyclic citrullinated peptide antibody.
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induced by IL-1b and TNFa in primary FLSs and was
inhibited by TGFb (Figure 5A). Consistently, FSTL1
p r o t e i ne x p r e s s i o nw a si n c r e a s e db yc o m b i n e dI L - 1 b
and TNFa treatment and inhibited by TGFb in primary
RA FLSs (Figure 5B).
Serum FSTL1 levels correlated with parameters of disease
activity in patients with RA
A significant positive correlation was seen between
serum FSTL1 levels and serologic parameters of disease
activity, including ESR, CRP, RF and ACPA, with levels
of clinical parameters including swollen joint count and
patient global VAS and, importantly, with disease activ-
ity, as indicated by the DAS28 score in the adult RA
population (Figure 6). In a multiple linear regression
analysis that used ln(FSTL1) as the dependent variable,
older age, female sex, ESR, RF and ACPA were indepen-
dently associated with FSTL1 (Table 3). The total r
2
value of this model was 0.45.
Effects of treatment on serum FSTL1 levels in patients
with RA
We performed follow-up studies of serum FSTL1 levels
in RA patients after treatment with infliximab and/or
DMARDs for 6 months (Figure 7). Among the 20 RA
patients enrolled in the follow-up studies were four with
ACR20, seven with ACR50, four with ACR70, and five
nonresponders. Serum FSTL1 levels in 14 patients with
active RA were significantly diminished following clini-
cal improvement with treatment (infliximab alone in
two patients, infliximab plus leflunomide in four
patients, infliximab plus leflunomide plus methotrexate
in two patients and leflunomide alone in six patients).
Only one early stage patient treated with leflunomide
alone who achieved an ACR20 response had a slight
increase in serum FSTL1 concentrations (10.0 μg/l
before treatment and 17.0 μg/l after treatment). Impor-
t a n t l y ,f o rt h ef i v ep a t i e n t sw h od i dn o ta c h i e v ea n
ACR20 response, serum FSTL1 levels did not change
significantly before and after treatment.
Discussion
In this study, we have found for the first time that
serum FSTL1 levels are significantly elevated in patients
with systemic autoimmune diseases, including RA, UC,
S L E ,S S ,S S ca n dP M / D M .F u r t h e r m o r e ,w eh a v e
revealed that serum FSTL1 levels are correlated with
serologic and clinical features of disease activity in the
RA patient population. Finally, we have observed that
serum FSTL1 levels are significantly decreased in RA
patients following successful treatment and clinical
improvement. These observations suggest that FSTL1
can serve as a reliable serological marker for disease
activity in the RA patient population.
We also systemically assessed FSTL1 expression in
adult RA patients for the first time. We found that
FSTL1 levels were also increased in the STs and SF of
RA patients. The strongest FSTL1 staining was detected
in the cytoplasm of synovial and capillary ECs from RA
synovium. Interestingly, we found that FSTL1 concen-
trations in serum were higher than those in synovial
fluid in the adult RA population, suggesting that the
source of FSTL1 was not limited to the synovium. In
fact, previous reports have shown that FSTL1 is widely
expressed in almost all organs, especially the lung and
Figure 3 (A) FSTL1 mRNA expression in cryogenic tissue samples from patients with RA (n = 14) and trauma controls (Con, n =8 ) .
Results are expressed in relative units, and horizontal lines represent means. The P values derived using Student’s t-test are indicated. (B) FSTL1
protein expression in representative tissue samples from trauma controls (N1-N4: N represents normal synovial tissues; 1-4 represents four
different trauma control individuals) and RA patients (RA1-RA5, RA represents RA synovial tissues; 1-5 represents five different RA patients). FSTL1
immunoreactive band appears as a band with electrophoretic mobilities corresponding to 46 kDa. b-Actin was used as loading control. (C)
FSTL1 concentrations in SF from trauma controls (n = 7) and RA patients (n = 13) and in serum from healthy individuals (n = 69) and RA
patients (n = 207). Values are means ± SEM. FSTL1, follistatin-like protein 1; RA, rheumatoid arthritis; SF, synovial fluid.
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Page 7 of 12heart in rat [2]. Moreover, FSTL1 is also referred as a
“myokine” because it is secreted into the peripheral
blood by cardiac and skeletal muscle [3,4]. Oshima et al.
[3] reported that FSTL1 is also secreted by ECs. Our
results indicate that FSTL1 stained strongly in inflam-
matory ECs. These data suggest that ECs are a potential
source of serum FSTL1, especially for those RA patients
with complications such as rheumatoid vasculitis, peri-
carditis and pleuritis. However, we did observe that
FSTL1 stained strongly in synovial cells and was
induced in FLS by proinflammatory cytokines from RA
patients. Therefore, we proposed that FLS is also the
source of elevated FSTL1 levels, at least in STs. For
these RA patients with lack of systemic arthritis symp-
toms, we could not exclude the possibility that FLS sti-
mulated continually by proinflammatory mediators
increased FSTL1 concentrations in STs and then
released FSTL1 into serum.
A variety of autoantibodies exist, and microvascular
EC injury frequently occurs among systemic autoim-
mune diseases, including RA, SLE, SS, SSc and PM/DM.
It has been recognized that EC damage is caused by cir-
culating immune complexes containing RF and other
autoantibodies that form deposits in vessel walls, where
they trigger an inflammatory reaction that leads to EC
injury [21,22]. Previous reports have shown that FSTL1
was secreted by ECs [4]. In agreement with those obser-
vations, we found that FSTL1 stains strongly in inflam-
matory ECs. These findings raised the possibility that
inflammatory ECs are responsible for high serum FSTL1
levels in those diseases. In addition, FSTL1 is also
known to be secreted into the peripheral blood by
Figure 4 Immunohistochemical detection of FSTL1 in synovial tissues. (A-D) Trauma control synovial tissues with normal synovium.
Synovial cells with little or weak FSTL1 immunostaining are shown. (E-H) RA synovial tissues. Hyperplastic synovial lining and sublining cells with
positive FSTL1 immunostaining are shown. All tissues were counterstained with hematoxylin. (A, C, E and G) Original magnification, ×100. (B, D,
F and H) Original magnification, ×400. The negative controls were stained with polyclonal goat IgG (original magnification, ×100) and are shown
in the insets (A-D). Arrows indicate capillary endothelial cells from trauma control with normal synovial tissues (B) and RA synovial tissues (F and
H). FSTL1, follistatin-like protein 1; RA, rheumatoid arthritis; IgG, immunoglobulin G.
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Page 8 of 12cardiac and skeletal muscle, especially by ischemic mus-
cle in a mouse model [3,4]. Skeletal muscle inflamma-
tion and injury could also lead to higher serum FSTL1
levels in PM/DM. However, serum FSTL1 levels were
not elevated in seronegative spondyloarthropathy,
including AS, PsA and ReA, possibly because of less fre-
quent autoantibody-mediated vascular injury and vascu-
litis. It remains to be seen whether elevated serum
FSTL1 levels found in systemic autoimmune diseases
are relevant to the autoimmune response underlying the
disease process.
Serum FSTL1 levels in RA and sSS patients were sub-
stantially higher than those in other patients. In fact, the
disease of most sSS patients was secondary to RA in the
present study. This finding may be explained by both
persistent synovitis of multiple joints and frequent extra-
articular manifestations in RA patients. Increased serum
FSTL1 levels could reflect not only chronic multiple
synovial joint inflammation but also systemic inflamma-
tion and tissue degradation.
Although the effects of increased FSTL1 on the inflam-
mation process were not assessed in this study, it has
been recently reported that FSTL1 is a novel proinflam-
matory mediator in a rodent animal model [5,10]. High
circulating FSTL1 levels in RA patients might possibly
cause deterioration in patients with arthritis by promot-
ing production of proinflammatory cytokines and chemo-
kines in arthritic joints. Another possibility is that FSTL1
promotes arthritis by increasing neovascularization of
inflammatory synovium. It has been established that
angiogenesis is associated with increased synovial inflam-
mation and pannus formation and that blocking angio-
genesis suppresses arthritis [23,24]. Previous studies have
shown that FSTL1 overexpression enhances revasculari-
zation in mouse ischemic limbs [4]. Therefore, increased
FSTL1 levels in RA could aggravate arthritis by FSTL1-
mediated neovascularization in RA STs. However, some
other reports have shown that FSTL1 plays immunosup-
pressive and immunomodulatory roles on immunity and
inflammation. FSTL1 plays an immunomodulatory role
in heart allograft transplantation [25] and ameliorates
arthritis in mouse models [26,27]. More recently, Adams
et al. [28] reported that FSTL1 protected the kidney from
acute nephrotoxic injury by inhibiting IL-1b expression.
Therefore, it could be that FSTL1 plays different roles in
varied cell and disease settings or at different stages in
the pathogenesis and progression of arthritis. It remains
to be determined whether different serum and tissue
FSTL1 levels play different roles in the adult RA popula-
tion. However, our findings that elevated serum FSTL1
levels and their correlations with inflammatory status in
patients with RA suggest its proinflammatory effects, at
least in the adult RA population.
Our data also reveal that serum FSTL1 levels correlate
with several important biologic and clinical markers of
disease activity, including ESR, CRP, swollen joint count,
patient global VAS and DAS28 score in the RA popula-
tion. Importantly, serum FSTL1 levels decreased
Figure 5 Upregulation of FSTL1 expression induced by inflammatory mediators in fibroblast-like synoviocytes (FLSs) from patients
with RA. (A) RA FLSs (n = 6) were treated with the indicated stimuli for 24 hours or were left untreated (medium). FSTL1 mRNA was
determined using RT-PCR. The results are presented in relative units, and the P values derived from paired t-tests are indicated for each
comparison. (B) FLSs from two RA patients (RA1 and RA2) were stimulated by combined IL-1b and TNFa or by TGFb, or they were left untreated
for 36 hours or 72 hours. Cell lysates were collected and analyzed by Western blot analysis using the anti-FSTL1 polyclonal antibody. b-Actin was
used as a loading control. FSTL1, follistatin-like protein 1; RA, rheumatoid arthritis; PCR, polymerase chain reaction; IL-1b, interleukin-1b; TNFa,
tumor necrosis factor a; TGFb, transforming growth factor b; LPS, lipopolysaccharide; bLP, bacterial lipoprotein; PIC, polyinosinic:polycytidylic acid.
Li et al. Arthritis Research & Therapy 2011, 13:R17
http://arthritis-research.com/content/13/1/R17
Page 9 of 12Figure 6 Correlation of serum FSTL1 levels with ESR (n =1 9 9 ) ,C R P( n =2 0 7 ) ,R F( n =2 0 7 ) ,A C P A( n =2 0 6 ) ,t e n d e r( n =8 1 )a n d
swollen (n = 81) joint counts, patient global VAS score (n = 81) and patient DAS28 score (n = 81) in adult RA population. Correlation
coefficients (r) and P values from the Spearman rank-order test are displayed. Each point represents an individual value. FSTL1, follistatin-like
protein 1; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; RF, rheumatoid factor; ACPA, anti-cyclic citrullinated peptide antibody;
VAS, visual analogue scale; DAS28, Disease Activity Score 28; RA, rheumatoid arthritis.
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Page 10 of 12markedly following clinical improvement. These data
indicate that serum FSTL1 could serve as a new biomar-
ker for disease activity in RA patients. A recent report
has shown that serum FSTL1 levels are slightly elevated
in systemic onset juvenile rheumatoid arthritis. How-
ever, it is premature to conclude that FSTL1 represents
a biomarker for the disease, because only small samples
with little clinical information were assessed in that
recent study [29].
In comparison to the existing markers, such as ESR
and CRP, serum FSTL1 was produced, at least partially,
at local inflammation sites, including arthritic joints and
blood vessels, which could reflect the status of tissue
damage more accurately than those traditional markers.
In addition, it has been observed in the clinic that some
patients have normal or low levels of ESR or CRP
despite extensive arthritis [30]. Serum FSTL1 levels in
these patients could be a useful inflammatory marker.
Serum FSTL1 levels were independently related to titers
of RF and ACPA, supporting the hypothesis that FSTL1
could be induced by immune complex-mediated vascu-
lar and tissue damage. In addition, RF and ACPA are
correlated with a worse prognosis and the presence of
aggressive disease [31]. Further study is required to
assess the relationship between serum FSTL1 levels and
joint damage and radiological progression in the RA
patient population.
Conclusions
FSTL1 levels are increased in systemic autoimmune dis-
eases. Serum FSTL1 levels reflect the inflammatory sta-
tus in RA patients. These results suggest that FSTL1
may serve as a novel biomarker for RA disease activity,
raising the possibility that FSTL1 levels may be potential
therapeutic targets in these diseases.
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